PCSK9 and acute coronary syndrome: Two single-center trials used optical coherence tomography to investigate the effects of PCSK9-antibodies vascular structure: Firstly, a retrospective study reported that treatment with evolocumab for 12 weeks increased fibrous-cap thickness and reduced the lipid-rich plaque proportion in 18 patients (intervention group) with acute coronary syndromes [9].